Tie-2 modulators and methods of use
Granted: July 12, 2007
Application Number:
20070161651
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
Loc169505 as modifiers of the apc and axin pathways and methods of use
Granted: June 21, 2007
Application Number:
20070141649
Human LOC169505 genes are identified as modulators of the APC and axin pathways, and thus are therapeutic targets for disorders associated with defective APC and axin function. Methods for identifying modulators of APC and axin, comprising screening for agents that modulate the activity of LOC169505 are provided.
Csnks as modifiers of the rac pathway and methods of use
Granted: June 21, 2007
Application Number:
20070141664
Human CSNK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of CSNK are provided.
Mracs as modifiers of the rac pathway and methods of use
Granted: June 21, 2007
Application Number:
20070142271
Human MRAC genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of MRAC are provided.
Prkcs as modifiers of the beta catenin pathway and methods of use
Granted: June 7, 2007
Application Number:
20070128606
Human PRKC genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of PRKC are provided.
Map2k6 as modifier of branching morphogenesis and methods of use
Granted: April 26, 2007
Application Number:
20070092875
Human MAP2K6 genes are identified as modulators of branching morphogenesis, and thus are therapeutic targets for disorders associated with defective branching morphogenesis function. Methods for identifying modulators of branching morphogenesis, comprising screening for agents that modulate the activity of MAP2K6 are provided.
Marks as modifers of the pten pathway and methods of use
Granted: March 15, 2007
Application Number:
20070059698
Human MARK genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that
c-Met modulators and methods of use
Granted: March 8, 2007
Application Number:
20070054928
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above,…
Mptens as modifers of the pten/igf pathway and methods of use
Granted: February 22, 2007
Application Number:
20070042371
Human MPTEN genes are identified as modulators of the PTEN/IGF pathway, and thus are therapeutic targets for disorders associated with defective PTEN/IGF function. Methods for identifying modulators of PTEN/IGF, comprising screening for agents that modulate the activity of MPTEN are provided.
Anaplastic lymphoma kinase modulators and methods of use
Granted: February 8, 2007
Application Number:
20070032515
The present invention comprises compounds and pharmaceutical compositions comprising the compounds that are inhibitors of ALK. The invention also comprises methods of using the compounds and compositions to treat diseases mediated by ALK, including diseases such as cancer, immunological disorders, cardiovascular diseases, and other degenerative disorders.
Tie-2 modulators and methods of use
Granted: December 28, 2006
Application Number:
20060293342
The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Tie-2. Methods of using the compounds and pharmaceutical compositions thereof to treat kinase-dependent diseases and conditions are also an aspect of the invention.
Genes upregulated in a tomato plant having an increased anthocyanin content phenotype
Granted: December 7, 2006
Application Number:
20060277631
Tomato anthocyanin vacuolar transporter (“MTP77”) and chalcone isomerase (“MTP96”) are up-regulated in tomato plants that overexpress the ANT1 gene. Plant transformation vectors comprising isolated MTP77 or MTP96 polynucleotides can be made to generate transgenic plants having increased anthocyanin content relative to control plants.
Dyrks as modifiersof the apc and axin pathways and methods of use
Granted: November 23, 2006
Application Number:
20060265763
Human DYRK genes are identified as modulators of the APC and Axin pathways, and thus are therapeutic targets for disorders associated with defective APC and Axin function. Methods for identifying modulators of APC and Axin, comprising screening for agents that modulate the activity of DYRK are provided.
LIMKs as modifiers of p53 pathway and methods of use
Granted: July 20, 2006
Application Number:
20060160764
Human LIMK genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of LIMK are provided.
Csnk1gs as modifiers of the p21 pathway and methods of use
Granted: November 10, 2005
Application Number:
20050251870
Human CSNK1G genes are identified as modulators of the p21 pathway, and thus are therapeutic targets for disorders associated with defective p21 function. Methods for identifying modulators of p21, comprising screening for agents that modulate the activity of CSNK1G are provided.
